Skip to main content
. 2022 May 23;9:887978. doi: 10.3389/fnut.2022.887978

FIGURE 3.

FIGURE 3

Total nasal and eye symptom scores at baseline (yellow/orange bars) and 12 weeks (blue bars) of participants who took the full course of 10–12 week trial intervention (n = 40). (A) Individual symptom scores and (B) total nasal and/or eye symptom scores. Higher scores represent more severe symptoms.